Company intelligence / Profile preview

Serodus

Ownership: Private
Development stage: Preclinical

Overview

The lead program SER150 has completed a phase 2 study in patients with diabetic kidney disease. The company has received approval for the next SER150 clinical study from New Zealand authorities in addition to ongoing approval in Australia. Patients have been randomized in Australia.

Therapeutic areas: OphthalmologyEndocrinologyNephrology
Modalities: PeptidesAnti-inflammatory compounds
Industry: Biotech

Drug pipeline

6 assets

SER120

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Serodus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serodus.

Explore the full profile